Comparative diagnostic performance of the new chromatographic Affimer^®-based rapid antigen detection against SARS-CoV-2 and other standard antigen tests for COVID-19 in a clinical setting

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

--- The study was subjected to revision by the Ethics Committee of Universidad Autonoma de Madrid (Arzobispo Morcillo, 4. 28029, Madrid) and the Institutional Review Board of Hospital Carlos III (Sinesio Delgado, 10. 28929, Madrid). --- Decision made, Full ethical approval was given to the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes